COMP <GO>
ONC vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
BeOne Medicines Ltd. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ONC 4
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $371.56 (-0.48%) • MKT CAP: $42.25B
roic
10.50%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.50% | 67.90% | +19.60 | ONC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 10.50% | 25.50% | -15.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 63.9x | 18.5x | +45.40 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.23% | 2.97% | -0.74 | JNJ | /fcf-yield <GO> |
| Operating Margin | 8.40% | 34.70% | -26.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 28.50% | -23.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 40.20% | 6.00% | +34.20 | ONC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.68 | 5.59 | +1.09 | ONC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | ONC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.6 | 62.1 | -8.50 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.08 | -0.10 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 123.6x | 23.0x | +100.60 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.25B | $662.49B | -$620.24B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONC REV | JNJ REV | ONC GROSS % | JNJ GROSS % | ONC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.34B | $94.19B | 87.5% | 67.9% | $941.7M | $19.70B |
| FY 2024 | $3.81B | $88.82B | 84.4% | 69.1% | -$633.3M | $19.84B |
| FY 2023 | $2.46B | $85.16B | — | — | -$1.27B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONC // BETA 0.98
JNJ // BETA 1.08